Tessa Romero
Stock Analyst at JP Morgan
(3.58)
# 683
Out of 4,817 analysts
58
Total ratings
39.53%
Success rate
8.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $9.34 | +82.11% | 5 | Mar 21, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $72 → $68 | $20.60 | +230.10% | 6 | Mar 5, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $9.72 | +291.15% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $0.67 | +2,133.14% | 4 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $0.37 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $29.87 | +3.78% | 5 | Oct 14, 2024 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $37.93 | +87.19% | 4 | Sep 5, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $5.90 | +391.53% | 3 | Aug 13, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $30 → $31 | $13.33 | +132.56% | 8 | Aug 12, 2024 | |
| AGIO Agios Pharmaceuticals | Reinstates: Neutral | $46 | $27.38 | +68.01% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $25 | $14.40 | +73.67% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $3.21 | +523.05% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $4.81 | +45.53% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $34.64 | +58.78% | 2 | Apr 25, 2023 |
Dyne Therapeutics
Mar 21, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $9.34
Upside: +82.11%
Biohaven
Mar 5, 2025
Maintains: Overweight
Price Target: $72 → $68
Current: $20.60
Upside: +230.10%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $9.72
Upside: +291.15%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $0.67
Upside: +2,133.14%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.37
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $29.87
Upside: +3.78%
Cytokinetics
Sep 5, 2024
Maintains: Overweight
Price Target: $65 → $71
Current: $37.93
Upside: +87.19%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $5.90
Upside: +391.53%
Edgewise Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $13.33
Upside: +132.56%
Agios Pharmaceuticals
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $27.38
Upside: +68.01%
Mar 25, 2024
Maintains: Overweight
Price Target: $29 → $25
Current: $14.40
Upside: +73.67%
Nov 28, 2023
Initiates: Overweight
Price Target: $20
Current: $3.21
Upside: +523.05%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $4.81
Upside: +45.53%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $34.64
Upside: +58.78%